Skip to main content

ADVERTISEMENT

Sharon Mates, PhD

Background: Somnolence and sedation are common treatment-emergent adverse events (TEAEs) reported with current antipsychotics. Lumateperone (lumateperone tosylate, ITI-007), a mechanistic...
10/08/2020
10/08/2020
Introduction: Lumateperone (lumateperone tosylate, ITI-007) is in late-phase clinical development for schizophrenia. Lumateperone has a unique mechanism of action that simultaneously modu...
11/22/2019
11/22/2019
Introduction: Patients with schizophrenia are a heterogenous population and understanding which factors may influence antipsychotic efficacy is important in improving outcomes. Lumatepero...
11/22/2019